Adeno‐associated virus mediated delivery of an engineered protein that combines the complement inhibitory properties of CD46, CD55 and CD59

ConclusionsWhen delivered to mice in vivo via an AAV vector, SACT and DTAC are capable of limiting human complement mediated damage. SACT and DTAC merit further study as potential therapies for complement mediated disorders when delivered via a gene therapy approach. This article is protected by copyright. All rights reserved.
Source: The Journal of Gene Medicine - Category: Genetics & Stem Cells Authors: Tags: Research Article Source Type: research